NASDAQ$ZNTL
Zentalis Pharmaceuticals Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported financial results for the fourth quarter and full year ended December 31, 2020, and highlighted recent corporate accomplishments.
Zentalis Pharmaceuticals reported a net loss of $40.4 million for the fourth quarter of 2020, compared to a net loss of $14.5 million for the same period in 2019. As of December 31, 2020, the company had cash, cash equivalents, and marketable securities of $338.5 million.
- Initiated multiple early-stage clinical trials evaluating ZN-c5, ZN-c3, and ZN-d5.
- Announced strategic collaboration with Tempus to expand and strengthen research and development capabilities.
- Zentera Therapeutics submitted two Investigational New Drug (IND) applications in China ahead of schedule.
- Presenting clinical data from the Phase 1 monotherapy trial of ZN-c3 at the upcoming AACR 2021 Annual Meeting.
Headline financials
Revenue & EPS history
Zentalis · Revenue · Quarterly
$400K
Forward guidance
Zentalis expects that its existing cash, cash equivalents and marketable securities will enable the Company to fund its operating expenses and capital expenditure requirements into 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2020
-1.4%
Avg return
Earnings day
-2.0%
Avg return
5 days after
+0.8%
Avg return
30 days after
60%
15 / 25 earnings
Positive
+14.5%
Q1 2023
Best reaction
-43.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +3.1% | -3.2% | — | |
| Q1 2026 | +3.9% | -1.7% | -15.0% | |
| Q3 2025 | +6.2% | +0.8% | +9.8% | |
| Q2 2025 | +5.1% | +2.2% | +26.8% | |
| Q1 2025 | -2.5% | +3.3% | +10.7% | |
| Q4 2024 | -12.6% | -15.0% | -23.5% | |
| Q3 2024 | -2.7% | -13.9% | -22.3% | |
| Q2 2024 | -8.8% | -12.5% | -10.6% | |
| Q1 2024 | +6.1% | +7.0% | -5.5% | |
| Q4 2023 | +10.0% | +8.5% | +11.9% | |
| Q3 2023 | -43.0% | -45.0% | -33.1% | |
| Q2 2023 | +5.3% | +11.2% | -0.5% | |
| Q1 2023 | +14.5% | +22.8% | +2.7% | |
| Q4 2022 | +1.2% | -2.1% | -9.1% | |
| Q3 2022 | -14.1% | -4.3% | -17.4% | |
| Q2 2022 | -0.1% | -7.3% | -8.1% | |
| Q1 2022 | -16.4% | -24.7% | +1.3% | |
| Q4 2021 | +7.6% | +5.7% | -3.2% | |
| Q3 2021 | +0.8% | -1.0% | -8.8% | |
| Q2 2021 | +4.9% | +7.1% | +39.0% | |
| Q1 2021 | -4.6% | -1.3% | -9.0% | |
| Q4 2020 | +1.4% | -0.7% | +45.7% | |
| Q3 2020 | -5.6% | -2.1% | +36.3% | |
| Q2 2020 | +1.0% | +7.2% | -10.6% | |
| Q1 2020 | +4.5% | +8.2% | +10.5% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro